Related Experiment Video
Updated: Feb 28, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Discovery of Obacunone as a TGR5 Agonist from Rhizoma coptidis: Affinity Screening, Functional Verification and
Gaojie Fu1, Maoting Liu2, Zenghao Bi2
1College of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
Abstract:
Rhizoma coptidis (RC), known as Huang Lian, is widely used for treating diabetes in Traditional Chinese Medicine. G protein-coupled bile acid receptor 1 (TGR5) is a potential therapeutic target for glucose-lipid metabolic disorders due to its capacity to stimulate glucagon-like peptide-1 (GLP-1) secretion. However, whether RC contains ingredients targeting TGR5 remains unclear. In this study, we screened 330 secondary metabolites of RC via molecular docking and identified obacunone as a top candidate. We confirmed binding using Cell Membrane Chromatography (CMC) and quantified affinity via Surface Plasmon Resonance (SPR), determining a KD of 101 μM. cAMP assays identified obacunone as an activator of TGR5. Subsequently, concentration-dependent cAMP assays characterized it as a partial agonist with an EC50 of 9.6 μM. Finally, transcriptomic profiling revealed a stress adaptation response, identifying Heme Oxygenase 1 (HMOX1) as the most significantly upregulated gene (padj = 9.99 × 10-72, log2FoldChange = 1.65). These findings contribute to understanding the pharmacological profile of RC and provide a screening example for identifying components with GPCR activity in RC.
Related Concept Videos
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Pharmacogenomics: Identification of New Drug Targets
Opioid Receptors: Overview
Drug Discovery: Overview
GPCRs Regulate Adenylyl Cylase Activity
GPCR Desensitization

